A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.
cMET Dysegulation Advanced Solid Tumors
DRUG: INC280
Incidence of Dose limiting toxiticites (DLTs), During the first 28 days on INC280 treatment; cycle = 21 days|Frequency of DLTs, During the first 28 days on INC280 treatment|Category of DLTs, During the first 28 days on INC280 treatment|AUClast for INC280, Treatment Cycle 1 Day 1 (C1D1), C1D7, C1D15, C2D1, C3D1|AUCtau for INC280, C1D1, C1D7, C1D15, C2D1, C3D1|Cmax for INC280, C1D1, C1D7, C1D15, C2D1, C3D1|Tmax, C1D1, C1D7, C1D15, C2D1, C3D1
Adverse events based on CTCAE grading and other safety variables (e.g. EGC readings, physical examination, vital signs and laboratory results)., Screening, until 30 days post-treatment
Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.